Consumer willingness to pay for a hypothetical Zika vaccine in Brazil and the implications

Roberto Lúcio Muniz Júnior, Isabella Piassi Godói, Edna Afonso Reis, Marina Morgado Garcia, Augusto Afonso Guerra Júnior, Brian Godman, Cristina Mariano Ruas

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
2 Downloads (Pure)


ABSTRACT : Background: Zika virus is a newly emerging infection, associated with increasingly large outbreaks especially in tropical countries such as Brazil. A future Zika vaccine can contribute to decreasing the number of cases and associated complications. Information about consumers’ willingness to pay (WTP) for a hypothetical Zika vaccine can help price setting discussions in the future in Brazil, starting with the private market. Methods: A cross-sectional study conducted among residents of Minas Gerais, Brazil, regarding their WTP for a hypothetical Zika Vaccine. The mean effective protection was 80%, with the possibility of some local and systemic side- effects. Results: 517 people were interviewed. However, 28 would not be vaccinated even if the vaccine was free. Most of the resultant interviewees (489) were female (58.2%), had completed high school (49.7%), were employed (71.2%), had private health insurance (52.7%), and did not have Zika (96.9%). The median individual maximum WTP for this hypothetical Zika vaccine (one dose) was US$31.34 (BRL100.00). Conclusion: Such discussions regarding WTP can contribute to decision-making about prices once a Zika vaccine becomes available in Brazil alongside other ongoing programs to control the virus.

Original languageEnglish
Pages (from-to)473-482
Number of pages10
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number4
Early online date4 Dec 2018
Publication statusPublished - 4 Jul 2019


  • Zika virus
  • Brazil
  • Zika vaccine
  • private pharmaceutical market

Cite this